Сравнение

CagriSema vs. Pemvidutide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследование на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	CagriSema	Pemvidutide
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between CagriSema and Pemvidutide?: CagriSema is classified as "Метаболизм", while Pemvidutide is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Pemvidutide?: The highest available evidence level is "РКИ на людях" for CagriSema and "Исследование на людях" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Pemvidutide in Germany and the United States?: Германия: CagriSema — Не одобрено, Pemvidutide — Не одобрено. США: CagriSema — Не одобрено, Pemvidutide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Pemvidutide

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between CagriSema and Pemvidutide?

CagriSema is classified as "Метаболизм", while Pemvidutide is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Pemvidutide?

The highest available evidence level is "РКИ на людях" for CagriSema and "Исследование на людях" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Pemvidutide in Germany and the United States?

Германия: CagriSema — Не одобрено, Pemvidutide — Не одобрено. США: CagriSema — Не одобрено, Pemvidutide — Не одобрено. These are factual summaries with source and review date on the individual pages.